Abstract
Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.
| Original language | English |
|---|---|
| Pages (from-to) | 650-654 |
| Number of pages | 5 |
| Journal | West Indian Medical Journal |
| Volume | 63 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2014 |
| Externally published | Yes |
ASJC Scopus Subject Areas
- General Medicine
Keywords
- Antigenic targets
- Cancer therapy
- Clinical benefits
- Monoclonal antibodies
Fingerprint
Dive into the research topics of 'Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS